ScienceThe case for wider use of polygenic risk scores in medicine
A post highlighting a new NEJM review argues that genomics is underused, citing a $20 cost—not charge—for polygenic risk scoring across multiple diseases.
TLDR
Highlighting a new NEJM review, a post argues that medical practice is missing out on genomics. It puts the cost of polygenic risk scoring for multiple diseases at $20, distinguishing cost from charge, and says the scores are informative for people in the highest-risk 5% across ancestries.
The case for wider use of polygenic risk scores in medicine
A post highlighting a new NEJM review argues that genomics is underused, citing a $20 cost—not charge—for polygenic risk scoring across multiple diseases.
TLDR
Highlighting a new NEJM review, a post argues that medical practice is missing out on genomics. It puts the cost of polygenic risk scoring for multiple diseases at $20, distinguishing cost from charge, and says the scores are informative for people in the highest-risk 5% across ancestries.
